TRAW
NASDAQTraws Pharma Inc.
News25/Ratings2
Price$0.92-1.09 (-54.23%)
2026-03-182026-06-22
News · 26 weeks45-67%
2025-12-282026-06-21
Mix3090d
- SEC Filings17(57%)
- Other7(23%)
- Insider3(10%)
- Offering1(3%)
- Earnings1(3%)
- Analyst1(3%)
Latest news
25 items- SECTraws Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramNEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, Traws, the Company)), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that an updated toxicology data package is in the process of being developed in response to information requirements from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the planned testing of tivoxavir marboxil (TXM) in a Phase 2a human influenza Challenge study. The updated data package is expected to be resubmitted to MHRA during the third quarter of 2026. "Based upon recent feedback and further guidance from the MHRA, we believe o
- ANALYSTTraws Pharma downgraded by Ladenburg ThalmannLadenburg Thalmann downgraded Traws Pharma from Buy to Neutral
- PRTraws Pharma Provides Regulatory Update on Influenza ProgramNEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, the Company)), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA). "Tivoxavir marboxil demonstrated potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile consistent with its use for bird flu treatment and prevention," said C. David Pauza, PhD Chief Science
- SECTraws Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form DEFA14A filed by Traws Pharma Inc.DEFA14A - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form DEF 14A filed by Traws Pharma Inc.DEF 14A - Traws Pharma, Inc. (0001130598) (Filer)
- SECTraws Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease OutbreaksBroad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing and future outbreaks Interactions planned with the US Centers for Disease Control and Prevention (CDC), and ongoing with the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC), and the African Medicines Agency (AMA) to fast-track clinical development, emergency manufacturing scale-up, and global access NEWTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW), a clinical-stage biopharmaceutical company d
- SECTraws Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form 424B5 filed by Traws Pharma Inc.424B5 - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form PRE 14A filed by Traws Pharma Inc.PRE 14A - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form EFFECT filed by Traws Pharma Inc.EFFECT - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form 424B3 filed by Traws Pharma Inc.424B3 - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form 10-Q filed by Traws Pharma Inc.10-Q - Traws Pharma, Inc. (0001130598) (Filer)
- SECTraws Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsPrivate financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027 Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent Advancing clinical candidates for the treatment of hantavirus infections NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today provided recent business highlights and reported financial results for the quarter ended
- SECSEC Form S-3 filed by Traws Pharma Inc.S-3 - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsNEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to advance potential clinical candidates for the treatment of hantavirus infections. Traws Pharma is responding to the threat of Hantavirus, a rodent-borne negative-strand RNA virus that typically results in a 30-50% fatality rate when transmitted to humans and which has been implicated as the cause of several cruise ship fatalities and serious illnesses in recent days1. The Company is already develop
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Traws Pharma Inc.SCHEDULE 13D/A - Traws Pharma, Inc. (0001130598) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Traws Pharma Inc.10-K/A - Traws Pharma, Inc. (0001130598) (Filer)
- INSIDERLarge owner Orbimed Advisors Llc bought $998,207 worth of shares (597,729 units at $1.67) (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- SECSEC Form 10-K filed by Traws Pharma Inc.10-K - Traws Pharma, Inc. (0001130598) (Filer)
- SECTraws Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Reports Full Year 2025 Results and Provides Business HighlightsTivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity, Ratutrelvir topline Phase 2a data show a differentiated profile versus PAXLOVID® in COVID patients, with good overall safety; final study analysis underway Private financing of up to $60M (with $10M of such amount upfront) offering of common stock and milestone-based and three-year warrants completed on April 15, 2026 supporting operations into Q1 2027 Investor Update call today, April 15, 2026 at 4:30 PM ET NEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company
TRAW FAQ
6 questionsWhere does TRAW stock trade?
Traws Pharma Inc. (TRAW) is listed on NASDAQ.What sector and industry is TRAW in?
Traws Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Traws Pharma Inc. go public?
Traws Pharma Inc. (TRAW) completed its IPO in 2013.What are analysts saying about TRAW?
Traws Pharma Inc. has had 2 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Neutral on 2026-06-15. Recent price targets cluster around $800.00.What companies are similar to TRAW?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TRAW side-by-side with any of them on Quantisnow.How can I track TRAW on Quantisnow?
Quantisnow aggregates Traws Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRAW to receive live email and push alerts on every new disclosure.